Evidence map›Paper›PMID 24732451›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2014

Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma.

Laura Bergadà, Judit Pallares, Arcidiacono Maria Vittoria, Anna Cardus, Maria Santacana, Joan Valls, Gonzalo Cao, Elvira Fernàndez, Xavier Dolcet, Adriana S Dusso and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Current Controversies on Adequate Circulating Vitamin D Levels in CKD.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Laura BergadàPathology Group, Pathology and Molecular Genetics Department, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida (Lleida Institute for Biomedical Research), Lleida, Spain.
Judit PallaresPathology Group, Pathology and Molecular Genetics Department, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida (Lleida Institute for Biomedical Research), Lleida, Spain.
Arcidiacono Maria VittoriaDivision of Nephrology, Hospital Universitari Arnau de Vilanova, University of Lleida, and Experimental Nephrology Department, IRB-Lleida, Lleida, Spain.
Anna CardusDivision of Nephrology, Hospital Universitari Arnau de Vilanova, University of Lleida, and Experimental Nephrology Department, IRB-Lleida, Lleida, Spain.
Maria SantacanaPathology Group, Pathology and Molecular Genetics Department, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida (Lleida Institute for Biomedical Research), Lleida, Spain.
Joan VallsBiostatistics Unit, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida, Lleida, Spain.
Gonzalo CaoLaboratory of Clinical Biochemistry, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida, Lleida, Spain.
Elvira FernàndezDivision of Nephrology, Hospital Universitari Arnau de Vilanova, University of Lleida, and Experimental Nephrology Department, IRB-Lleida, Lleida, Spain.
Xavier DolcetPathology Group, Pathology and Molecular Genetics Department, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida (Lleida Institute for Biomedical Research), Lleida, Spain.
Adriana S DussoDivision of Nephrology, Hospital Universitari Arnau de Vilanova, University of Lleida, and Experimental Nephrology Department, IRB-Lleida, Lleida, Spain.
Xavier Matias-GuiuPathology Group, Pathology and Molecular Genetics Department, Hospital Universitari Arnau de Vilanova, University of Lleida, and IRB-Lleida (Lleida Institute for Biomedical Research), Lleida, Spain.
Biomedical Research Institute of Lleida · ESUniversitat de Lleida · ESHospital Universitari Arnau de Vilanova · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D (VD) deficiency has been suggested as a risk factor for cancer. One recognized mechanism is that the low-serum 25-hydroxyvitamin D (25(OH)D) of VD deficiency reduces intratumoral 25(OH)D conversion to 1α,25-dihydroxyvitamin D (1,25D, the hormonal form of VD), compromising 1,25D-VD receptor (VDR) antitumoral actions. Reduced tumoral VDR and increased CYP24A1, the enzyme that degrades 1,25D and 25(OH)D, further worsen cancer progression. Importantly, in cells expressing CYP27A1 and/or CYP2R1, which convert inert VD into 25(OH)D, low-serum VD may reduce intratumoral 25(OH)D synthesis thereby compromising VDR antitumoral actions because 25(OH)D can activate the VDR directly and enhance 1,25D-VDR action. Therefore, this study examined whether abnormal endometrial expression of CYP27A1 and/or CYP2R1 may impair VDR-antiproliferative properties in endometrial carcinoma (EC). Immunohistochemical analysis of tissue microarrays of normal human endometrium (NE; n=60) and EC (n=157) showed the expected lower VDR expression in EC (P=0.0002). Instead, CYP24A1 expression was lower in EC compared with NE, while CYP27A1 and CYP2R1 expressions were higher (P=0.0002; P=0.03). Furthermore, in NE and EC, CYP2R1 and CYP27A1 expression correlated directly with nuclear VDR levels, an indicator of ligand-induced VDR activation, and inversely with the proliferation marker Ki67. Accordingly, in the endometrioid carcinoma cell lines IK, RL95/2 and HEC1-A, which express VDR, CYP27A1, and CYP2R1, VD efficaciously reduced cell viability and colony number, with a time course that paralleled actual increases in both intracellular 25(OH)D and nuclear VDR levels. Thus, VD may protect from EC progression in part through increased intratumoral 25(OH)D production by CYP27A1 and CYP2R1 for autocrine/paracrine enhancement of 1,25D-VDR-antiproliferative actions.

Indexed as

AdultAgedAged, 80 and overCase-Control StudiesCell Line, TumorCell ProliferationCholecalciferolCholestanetriol 26-MonooxygenaseCytochrome P450 Family 2Endometrial NeoplasmsEndometriumFemaleHumansMiddle AgedReceptors, CalcitriolCholecalciferolCholestanetriol 26-MonooxygenaseCYP27A1 protein, humanCYP2R1 protein, humanCytochrome P450 Family 2Receptors, Calcitriol

Identifiers

PMID24732451
OpenAlexW1964653778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.